M. Tang

发表

Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates*

J. Tso, M. Vásquez, N. Tsurushita, 2004, Journal of Biological Chemistry.

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

John C. Davis, B. Rojkovich, J. Grogan, 2012, Arthritis Research & Therapy.

Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

J. Sheridan, J. Elkins, V. Vexler, 2011, Multiple sclerosis.

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease

D. Danilenko, M. Keir, M. Tang, 2018, Alimentary pharmacology & therapeutics.

This information is current as Longer Serum Half-Life An Engineered Human IgG 1 Antibody with

N. Tsurushita, Stephen Keller, P. Hinton, 2005 .

Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

R. Maciuca, J. Kenny, L. Dickmann, 2016, Journal of clinical pharmacology.

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.

G. Jayson, M. Ranson, G. Groenewegen, 2005, European journal of cancer.

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity.

N. van Bruggen, Z. Fayad, D. Duprez, 2015, JACC. Cardiovascular imaging.

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis

L. Gibiansky, S. O’Byrne, M. Tang, 2017, Journal of clinical pharmacology.

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis

M. Kågedal, Angelica L. Quartino, T. Lu, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers

A. Boruvka, Han Ting Ding, M. Tang, 2021, Advances in Therapy.

An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers

M. Tang, H. Tyrrell, S. Tole, 2021, Advances in Therapy.

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

J. Ribbing, S. Jönsson, R. Bruno, 2022, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

J. Kierkuś, K. Park, M. Tang, 2021, Inflammatory bowel diseases.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

T. Waldmann, Darby J. S. Thompson, S. Srivastava, 2003, Journal of autoimmunity.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease

P. Rutgeerts, D. Hommes, G. Van Assche, 2005, Gut.

An Engineered Human IgG1 Antibody with Longer Serum Half-Life

N. Tsurushita, Stephen Keller, P. Hinton, 2006, The Journal of Immunology.

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

J. Mansfield, P. Rutgeerts, S. Vermeire, 2014, The Lancet.

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

J. Mansfield, P. Rutgeerts, J. Egen, 2012, Gut.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

S. Dutta, A. Othman, M. Tang, 2014, Clinical Pharmacokinetics.

A Guide to Rational Dosing of Monoclonal Antibodies

D. Allison, A. Joshi, Y. Xin, 2012, Clinical Pharmacokinetics.

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Teck Kiang Tan, J. Mansfield, Fraser Cummings, 2021, The lancet. Gastroenterology & hepatology.

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients

A. Tolcher, C. Takimoto, C. Ng, 2009, Cancer Chemotherapy and Pharmacology.

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

Jamal Zweit, Manfred Herold, Gordon C Jayson, 2002, Journal of the National Cancer Institute.

Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

Heather Myler, John Kamerud, Hossein Salimi-Moosavi, 2011, The AAPS Journal.

Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis

John C. Davis, J. Mandema, M. Tang, 2015, Journal of clinical pharmacology.

Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

John C. Davis, J. Grogan, F. Hsieh, 2014, Arthritis Research & Therapy.

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

J. Ribbing, M. Tang, Rong Zhang, 2022, CPT: pharmacometrics & systems pharmacology.